Our history

Always up to date – We develop everyday solutions for a better tomorrow

From innovation research to everyday life in the future: Phi-Stone AG connects the latest scientific findings with the development of innovative products.

The partnership with the University of Kiel University secures and strengthens our leading position by enriching the market with pioneering solutions through continuous research.

Our
Mission

Details

2024

Expansion of sales structures

Expansion of sales structures for further pharmaceutical applications of tetrapodal zinc oxide in: cosmetic products, medical products and pharmaceuticals.

2023

New production facility for tetrapodal zinc oxide

Start of the construction of a new production facility in Flintbek (Schleswig-Holstein) for the large-scale production of tetrapodal zinc oxide according to industrial GMP standards.

2022

Cooperation with KES Pharma

Cooperation with KES Pharma to develop and market several cosmetic products with tetrapodal zinc oxide.

First presentation Afinovir

First presentation of „Afinovir® Wound protection gel“ at the ExpoPharm 2022 in Munich.

2021

CE-Declaration of conformity

CE Declaration of Conformity for „Afinovir® wound protection gel“, the world´s first medical product with tetrapodal zinc oxide.

2019

GMP-Certification

Start of GMP-certified production of our active ingredient, „Zinc oxide, tetrapodal“ to alleviate herpes symptoms.

2017

Foundation of the Phi-Stone AG

2015/16

Prototype development for an industrial company

Foundation of the FPT Fluid- und Prozesstechnik GmbH. The EU-funded cross-border Interreg-Project „Rollflex“ starts with Denmark.

2014

Moving to Kiel

The BMWI-funded ZIM-Project „Development of a shielding foil for electromagnetic waves of a defined frequency to protect data carriers (NanoMet)“starts.